We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 22

U.S. drug prices challenged
  • Gowling WLG
  • USA
  • January 20 2010

In December, brand pharmaceutical companies defended themselves before the House Energy and Commerce health panel against complaints over reports, including one by the AARP (which represents 40 million older Americans), that drug prices continued to outstrip inflation in 2009.


Digital Economy Bill: controversial online copyright infringement provisions
  • Gowling WLG
  • United Kingdom
  • December 17 2009

The Digital Economy Bill had its second reading in the House of Lords this month.


Guangzhou passes legislation to bolster intellectual property rights protection at exhibitions
  • Gowling WLG
  • China
  • August 27 2009

Guangzhou passes the Measures on Protection of Intellectual Property Rights at Exhibitions in the city's 87th Executive Session of the 13th Administration.


IP in the UK budget
  • Gowling WLG
  • United Kingdom
  • April 28 2009

A first glance through the Budget - and the 222 pages of notes produced by the Treasury - didn't look promising.


PMPRB to require reporting of payments to third parties
  • Gowling WLG
  • Canada
  • August 21 2008

In separate announcements issued this week, the Patented Medicine Prices Review Board (PMPRB) has ended months of consultation and speculation by announcing that it will implement a policy change, first reported in its April 2007 NEWSletter, to require that patentees report all rebates and discounts, including payments made to third parties, in their filings on the prices of patented medicines.


Amendments to the Patented Medicines (Notice of Compliance) Regulations - registered on June 12, 2008
  • Gowling WLG
  • Canada
  • June 19 2008

In our Pharmacapsules edition that was published on May 8, 2008, we reported on the proposed amendments to the Patented Medicines (Notice of Compliance) Regulations ("Regulations") that the Canadian Government recently published in the Canada Gazette.


Trade-Marks Office tightens Official Mark practice after Federal Court sees unfairness in Registrar’s decision
  • Gowling WLG
  • Canada
  • May 30 2008

In See You In Canadian Athletes Fund Corporation v. Canadian Olympic Committee, 2007 FC 406, the Federal Court of Canada quashed the Registrar’s decision to grant Official Mark protection in the absence of adequate evidence of adoption and use of the marks.


A new discussion paper from the PMPRB
  • Gowling WLG
  • Canada
  • February 7 2008

The Patented Medicine Prices Review Board (PMPRB) has issued a discussion paper containing some specific proposals and options related to: its review of the Excessive Price Guidelines; and the controversy surrounding the implications of the Federal Court of Canada decision in the LEO Pharma case on the reporting of discounts and rebates.


PMPRB issues discussion paper on options to address the Federal Court decision in LEO Pharma
  • Gowling WLG
  • Canada
  • February 6 2008

The Patented Medicine Prices Review Board (PMPRB) has issued a discussion paper outlining a series of options to address the implications of the Federal Court of Canada decision in the LEO Pharma case.


New regulations respecting benefits and promotional allowances in Québec
  • Gowling WLG
  • Canada
  • November 16 2007

The Government of Québec has introduced new regulations under the Act Respecting Prescription Drug Insurance governing the rebates and other benefits offered by drug manufacturers to pharmacists.